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Abstract
Introduction: Up to 30% of individuals treated with antiretroviral therapy (ART) during chronic
HIV fail to recover CD4 counts to >500 cells/mm3 and up to 10% have quantifiable HIV RNA in
cerebrospinal fluid (CSF), termed CSF escape, despite plasma viral suppression < 50 copies/mL.
Previous studies have shown that ART initiation in the earliest stage of identifiable infection,
acute HIV infection (prior to antibody seroconversion), may limit viral reservoir establishment
and systemic immune activation and may improve clinical outcomes. We investigated the
frequency, associations, and outcomes of suboptimal CD4 recovery (Project 1) and CSF escape
(Project 2) after ART started during acute HIV infection (AHI).
Methods: Thai participants with laboratory-confirmed diagnosis of AHI (Fiebig stages I to V)
were started immediately on ART and followed longitudinally with blood sampling,
neuropsychological and neurobehavioral testing, and optional lumbar puncture. For Project 1,
participants with ≥48 weeks of documented HIV RNA <50 copies/mL were stratified by CD4
count at latest study visit to suboptimal recovery (SR; CD4<350 cells/mm3), intermediate
recovery (IR; 350≤CD4<500), and complete recovery (CR; CD4≥500). To assess determinants
of CD4 recovery, clinical and laboratory parameters were evaluated at pre-ART baseline and
latest study visit. Additional inflammatory and neurobehavioral endpoints were examined at
baseline and 96 weeks. For Project 2, participants who underwent blood sampling and optional
CSF sampling at weeks 24 and 96 were assessed for CSF escape. HIV RNA was quantified using
Roche Amplicor and COBAS TaqMan assays with a lower limit of quantitation of 20-50
copies/mL in plasma and 80 copies/mL in CSF. Participants with quantifiable CSF HIV RNA
greater than that in plasma during ART were identified as cases of CSF escape.

Results, Project 1: Of 304 participants (96% male, median 26 years old) evaluated after median
144 (range 60-420) weeks of ART initiated at median 19 days (range 1-62) post-exposure, 3.6%
(n=11) had SR, 14.5% (n=44) had IR, and 81.9% (n=249) had CR. Degree of CD4 recovery
occurred early following ART. Timing of ART initiation by Fiebig stage did not affect CD4
count during treatment. Pre-ART CD4 count in SR compared to CR participants was 265 vs 411
cells/mm3 (p=0.002). Following ART, the CD8+ T cell count (p=0.001) and CD4/CD8 ratio
(p=0.047) were lower in SR compared to CR participants. Compared to the CR group at week
96, the combined SR and IR groups had higher sCD14 (p=0.008) and lower IL-6 (p=0.04) in
plasma, without differences in neuropsychological or psychiatric indices. After adjusting for
duration of ART, baseline HIV-RNA, and baseline CD4 count, odds of CD4 recovery < 500
cells/mm3 were higher in those with baseline CD4/CD8 ratio < 1 (odds ratio 3.2, p=0.01), onART CD4/CD8 ratio < 1 (odds ratio 2.4, p=0.007), and on-ART CD8 count < 500 cells/mm3
(odds ratio 3.1, p=0.0005).
Results, Project 2: 204 participants had paired blood and CSF sampling in at least one visit at
baseline, week 24, or week 96. The participants were 98% male (199/204) with median age 26
years and baseline Fiebig stage 3 (96/204, 47%), CD4 count 386 cells/mm3, and plasma HIV
RNA 5.87 log10 copies/mL. ART was started at a median of 19 days post estimated infection. At
baseline, 126/165 participants (76%) had quantifiable CSF HIV RNA (median 3.13 log10
copies/mL). At week 24 (n=90), two participants (2%) had quantifiable CSF HIV RNA, with one
case of CSF escape identified with plasma HIV RNA < 50 copies/mL and CSF HIV RNA 2.50
log10 copies/mL. At week 96 (n=55), one participant (2%) had quantifiable CSF HIV RNA,
which did not meet criteria for CSF escape. The two other cases of quantifiable CSF HIV RNA
were due to plasma HIV RNA > CSF HIV RNA. The participant with CSF escape was treated

with efavirenz, tenofovir, and lamivudine and had a CD4 count of 840 cells/mm3 and CSF WBC
and CSF protein of 4 cells/mm3 and 30 mg/dL. His MRI at week 24 showed a small nonspecific
T2/FLAIR hyperintense focus in the right high frontal white matter. He did not have a lumbar
puncture performed at baseline nor at subsequent visits.
Conclusions: Despite immediate and sustained treatment in AHI, suboptimal CD4 recovery is
observed in rare individuals, associated with low pre-ART CD4 count as well as persistent low
CD8 count and CD4/CD8 ratio during treatment. While levels of CSF HIV RNA in untreated
AHI are high, initiating treatment during AHI results in a very low rate of CSF escape in the first
two years of ART. The low rate of CSF escape may also be impacted by high levels of adherence
to ART in this cohort or the short duration of ART. Longitudinal monitoring will be required to
verify if CSF escape remains rare under long-term ART in early treated individuals.
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Introduction
HIV Infection in the Era of Antiretroviral Therapy
Throughout its storied impact on human health, the human immunodeficiency virus (HIV)
epidemic has uniquely intersected with issues of stigma, mental health, sexual identity and
expression, and poverty, and once spelled near-inevitable morbidity and mortality for individuals
already marginalized by their communities. Now, more than 60% of people living with HIV are
receiving antiretroviral therapy (ART), transforming HIV infection into a chronic manageable
condition affecting an estimated 37.9 million people worldwide [1]. Substantial progress has been
made in reducing HIV transmission, improving screening, and expanding access to ART.
However, the number of people living with HIV likely will continue to increase in more than 100
countries, as estimated by incidence-prevalence ratios [1]. Thus, with approximately 23.3 million
people on ART and growing, there is considerable interest in long-term outcomes of people on
virally suppressive ART. Chronic complications of treated HIV infection include systemic
immune dysregulation and inflammation, accelerated cardiovascular disease, insulin resistance,
reduced bone mineral density, chronic kidney disease, and HIV-associated neurocognitive
disorders (HAND) [2-5]. Notably, this should be distinguished from chronic complications
thought to be related to long-term use of certain ART medications [5]. In particular, this section
will draw attention to the persistence of immune dysregulation, neurocognitive impairment, and
HIV reservoirs, even in the era of ART and in the setting of plasma viral suppression.
Early in the HIV epidemic, even before it was identified as the cause of acquired
immunodeficiency syndrome (AIDS), immune activation was described in tandem with very low
CD4+ T cell counts in the first case reports of AIDS [6]. Lymphocytes were found to have high
expression of CD38, a marker of T cell activation, which were later found to independently predict
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more rapid disease progression [7, 8]. Likewise, the markers of innate immune activation neopterin
and ß2-microglobulin were found to be elevated in untreated HIV infection, which in particular
correspond to monocyte and macrophage activation, respectively [8, 9]. Inflammatory and
coagulation indices are also elevated in untreated HIV infection, such as interleukin-6, D-dimer,
C-reactive protein, and soluble CD14, and additionally predict morbidity and mortality [10-12].
Even with effective plasma viral suppression on ART, T cell activation persists [13], and
inflammatory indices are elevated and predict non-AIDS-defining adverse events independent of
pre-ART nadir and recent CD4+ T cell count [14, 15].
Mechanistically, many factors may contribute to persistent immune dysregulation in
treated HIV infection. Gut mucosal CD4+ T cells are rapidly depleted in early HIV infection, and
the resultant mucosal inflammation damages the epithelial barrier of the gastrointestinal tract
leading to intestinal microbial translocation [16]. Both intestinal CD4+ T cell depletion and
microbial translocation are thought to contribute to persistent immune activation [17, 18]. Also
occurring early in infection, HIV replication in lymphoid tissues results in collagen deposition and
fibrosis, likely due to increased T regulatory cell activity and TGF-ß secretion. Lymphatic fibrosis
contributes to poor CD4+ T cell reconstitution and immune dysregulation [19, 20]. Co-infection
with pathogens such as cytomegalovirus may also be implicated in residual inflammation in treated
HIV infection [21, 22]. Beyond T cell activation, other findings of T cell dysregulation have been
described in HIV infection, which are only partially ameliorated with ART. T cell exhaustion is
marked by upregulation of inhibitory receptor programmed death 1 (PD-1), results in impairment
of T cell activity, including reduced cytokine secretion, proliferative capacity, and cytotoxic
effector function [23], and occurs in HIV-specific CD8+ T cells in treatment-naïve participants
[24]. Other markers such as Tim-3 may also be upregulated in exhausted and impaired T cells in
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HIV infection [23, 25]. Commencement of ART only partially downregulates these markers of T
cell exhaustion [26]. CD8+ T cells are not only activated and exhausted in untreated and treated
HIV infection, their population is also markedly expanded [27]. The coalescence of CD4+ T cell
depletion and CD8+ T cell expansion is captured by the metric of the CD4/CD8 ratio, which is
increasingly recognized as a measure of immune activation that predicts worse clinical outcomes
[28]. Ultimately, inflammation, coagulopathy, and immune activation in ART-suppressed HIV
infection are multifactorial processes that contribute to an elevated risk of non-AIDS-related
morbidity and mortality. Importantly, immune dysregulation has been linked to poor CD4+ T cell
recovery even while on long-term ART [13, 29], a main subject of this thesis.
HIV-associated dementia (HAD) occurred in up to 30% of patients with AIDS-defining
illnesses prior to the advent of ART. However, with the widespread use of ART, the burden of
HAD has substantially decreased while the burdens of milder forms of HAND have increased,
including asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder
(MND) [2, 30]. This occurs despite the widespread availability of ART in resource-rich settings
and despite effective virological suppression systemically and in the central nervous system
(CNS). Interestingly, neurocognitive impairment seems to be primarily in the motor, cognitive,
and verbal domains in the pre-ART era, and in memory and executive function in the ART era [2].
The increased prevalence of HAND even in the era of ART raises the question of whether ART is
effective at suppressing viral replication in the central nervous system (CNS) or modulating
neuroinflammation, or whether there are other mechanisms driving persistent neurocognitive
impairment including irreversible CNS injury prior to ART initiation, ß-amyloid deposition in the
brain, neurovascular injury, or antiretroviral neurotoxicity [2]. Generally, most studies appear to
point to a net neurocognitive benefit of ART, though the neurotoxicity of efavirenz is well-
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described and recognized [31]. It is still unknown whether ART is sufficient to prevent HAND,
though very early treatment initiation may prevent it in a majority of individuals [4, 32]. Because
milder HAND remains prevalent in people living with HIV and on ART, specific treatment for
HAND can be considered in these individuals including antiretroviral switch, treatment
intensification, and potentially newer drugs under investigation such as cenicriviroc and
natalizumab [4, 33].
Chronic complications of treated HIV infection, including immune dysregulation and
HAND, may stem from persistence of HIV reservoirs, which are not eradicated by long-term ART.
HIV reservoirs are established early in infection, may be maintained chronically by ongoing HIV
replication, and are thought to predominantly come from resting memory CD4+ T cells that harbor
latent proviral DNA [34, 35]. Other important anatomic reservoirs include the genital tract, the
gastrointestinal tract, lymphoid tissues (including thymus, gut-associated lymphoid tissue, and
lymph nodes), and the CNS. ART may reduce, but does not completely eliminate, reservoirs as
measured by total HIV DNA load [36]. Lamers et al demonstrated measurable HIV DNA is present
in a majority of autopsy tissues, including brain, sampled in various anatomical sites of individuals
on ART with low or undetectable viral load prior to death [37]. There may be some effect of timing
of ART initiation upon HIV reservoir size. Earlier treatment in perinatal HIV infection is
associated with smaller peripheral blood proviral reservoir size in adolescence [38]. Likewise,
treatment during acute HIV infection reduces systemic HIV reservoirs compared to individuals
treated for chronic infection. Conversely, progression throughout the stages of acute HIV infection
associates with increased HIV reservoir seeding [39]. Specifically within the CNS compartment,
early treatment during acute infection has not yet proven to reduce CNS reservoir size, though
other benefits have been demonstrated in terms of decreased neuroinflammation and HIV-specific

5
immune responses in CSF [40]. Cerebrospinal fluid (CSF) escape of HIV, another main subject of
this thesis, describes a discordance of detectable CSF HIV RNA alongside undetectable plasma
HIV RNA, may be an indicator of active viral replication from CNS reservoirs, and is described
later in further detail [41]. Altogether, despite ART, HIV infection remains persistent in the form
of difficult-to-eradicate reservoirs in various anatomical compartments. Though HIV remission
has been achieved to date in two individuals via hematopoietic stem cell transplant [42, 43],
reservoirs represent a chronic disease burden for the vast majority of people living with HIV.
Acute HIV Infection: The Earliest Events
Acute HIV infection (AHI) describes the earliest detectable stages of HIV infection, when
HIV serology remains non-reactive or inconclusive yet viral replication is detectable in tissue and
blood [44]. After exposure and transmission, HIV replicates in the mucosa, submucosa, and
lymphoid tissues and is not yet detectable in plasma, which comprises the eclipse phase.
Thereafter, HIV RNA becomes detectable in plasma, followed by a predictable sequence of
detectable markers of HIV infection [45].
Based on this sequence, AHI is classified by Fiebig stages using laboratory criteria. In AHI,
there are sequential assays that test positive: detection of HIV RNA, detection of p24 antigen, antiHIV-1 (groups M and O) recombinant gp41 IgM enzyme immunoassay, and Western blot (to HIV1 gp160, gp120, p65, p55, gp41, p40, p31, p24, and p18) (Table 1). Fiebig stage V is estimated to
last up to approximately 90 days post-infection [44]. Fourth-generation antibody-antigen testing is
standard in the United States and captures Fiebig stages II-VI of AHI, but still misses the pre-p24
eclipse period of AHI. Given this as well as the fact that newly HIV-infected individuals may
present later due to the nonspecific symptoms of acute antiretroviral syndrome, diagnosis of AHI
may still be delayed or missed [46].
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Table 1. Fiebig stages of acute HIV infection.
Stage designation
Laboratory criteria (additive to prior Fiebig stage)
Fiebig I
RNA+, p24 antigen–
Fiebig II
p24 antigen+, IgM–
Fiebig III
IgM+, Western blot –
Fiebig IV
Western blot indeterminate
Fiebig V
Western blot+ without p31 protein band
Fiebig VI
Western blot+
Data from [44].

Though several routes of HIV transmission are possible (e.g. cervicovaginal, intravenous,
penile, rectal), CD4+ T cells and Langerhans cells are likely the first targets of HIV infection. Soon
thereafter, viral replication occurs substantially in the gut-associated lymphoid tissues (GALT)
within CD4+ T cells expressing high levels of CCR5 coreceptor and then spreads systemically,
concurrent with a rapid increase in plasma HIV RNA and a steep decline in peripheral CD4+ T
cells. Indeed, the vast majority of transmitted and founder viruses are shown to be R5-tropic [45].
If AHI is left untreated, the CD4 count transiently increases, and later progressively declines, while
plasma viral load decreases to a steady state set point [45, 47, 48].
The immune system rapidly responds to AHI. The frequent occurrence of acute
antiretroviral syndrome suggests a systemic inflammatory response to AHI. Both soluble and
cellular markers of immune activation appear within the first few days of HIV infection, including
acute phase reactants, cytokines, and CD8+ T cell activation [49-51]. Early CD8+ T cell activation
leads to proliferation that has been shown to improve virological control; however, T cell
activation after the first few weeks of infection seem to contribute to immune dysfunction [52].
From the RV254 cohort of Thai participants with AHI, Fiebig I AHI is associated with lower
immune activation compared to later Fiebig stages, as measured by soluble CD14 (sCD14),
CD4/CD8 ratio, and CD8+ T cell activation [53]. Thus, the immune response appears to be
beneficial very early within AHI but may contribute to dysfunction at later stages [54].
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Additionally, a substantial proportion of CD4+ T cells in the GALT that are depleted during AHI
are Th17 cells that secrete/respond to IL-17, which are integral to maintaining the integrity of the
GI tract mucosal barrier. Depletion of Th17 cells in AHI compromises the mucosal barrier,
resulting in translocation of GI tract microbes and microbial products that contributes to systemic
inflammation seen in AHI [54]. Finally, immune activation markers in CSF are elevated in a subset
of individuals with AHI; they include neopterin (marker of macrophage activation) and
chemokines CXCL10 and CCL2 (immune cell trafficking) [55].
Given that immune dysfunction may arise even within early HIV infection, ART initiation
in AHI continues to be investigated for potential therapeutic benefit. Within the RV254 cohort,
ART in AHI reduced markers of inflammation (C-reactive protein, sCD14, hyaluronic acid) and
even normalized some when compared to HIV-negative controls (tumor necrosis factor, soluble
IL-6 receptor, D-dimer) [56]. Indeed, treatment during the earlier stages of Fiebig I and II AHI
was found to have a unique benefit compared to that in Fiebig III, in that it restored mucosal Th17
numbers and polyfunctionality and reversed peripheral and mucosal CD8+ T cell activation [57].
However, initiation of ART in Fiebig I does not appear to confer a unique benefit for restoring
CD4/CD8 ratio when compared to initiation of ART at later Fiebig stages, potentially suggesting
some degree of irreversible immune activation conferred by AHI [53]. When comparing CSF
versus plasma concentrations of neopterin (marker of macrophage activation) and the chemokines
CXCL10 and CCL2 (immune cell trafficking), they remained elevated in plasma but in CSF were
normalized to levels seen in HIV-negative controls. This suggests a unique benefit of early ART
initiation for reducing and reversing neuroinflammation [58].
Studies of AHI and immediate treatment initiation also allow for an assessment of early
reservoir establishment and whether this process is modifiable with early interventions, with the
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prospect of achieving ART-free HIV remission. The reservoir, as measured by HIV DNA, is
established in early infection [39, 59]. Reservoir size also increases throughout the stages of AHI.
Participants identified during Fiebig I had lower total blood and gut HIV DNA compared to those
in Fiebig stages II and III [39, 53]. Factors impacting viral reservoir size continue to be an area of
active investigation but include an early CD8+ T cell response [60] as well as timing of ART. If
early infection is allowed to progress without immediate ART intervention, the HIV reservoir
dramatically increases and reaches its set point [59]. Early treatment in AHI can significantly
reduce this reservoir size [39, 59], and one study has shown that this reduction is sustainable over
three years of ART [61]. Importantly, early treatment alone has not shown to produce ART-free
HIV remission, even with undetectable HIV RNA or DNA in multiple blood and tissue samples.
Even with treatment started at Fiebig I and maintained more than two years, participants
experienced rapid viral rebound just weeks after analytical treatment interruption [62]. One
participant was able to remain aviremic for more than seven months after analytical treatment
interruption [63]. Indeed, even ART initiation within as short as 30 hours of life was not enough
to induce ART-free remission in the Mississippi baby [64, 65]. Looking specifically at the CNS
compartment, there is evidence of localized benefit of early ART by way of reduced and delayed
immune activation and HIV-specific antibodies in CSF [58, 66], but there also is evidence of a
persistent HIV-specific CD8+ T cell response in CSF [67]. It is increasingly thought that immune
trafficking, signaling, and activation are linked to establishment and persistence of the HIV
reservoir [54, 68]. CNS reservoir establishment and persistence may be a consequence of immune
cell trafficking, both early in infection and throughout chronic infection. Because there appear to
be delays in immune response (perhaps due to trafficking) as well as virological dynamics in the
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CNS, there may be a unique benefit of early ART in reducing HIV reservoirs in the CNS as
compared to systemic sites of HIV persistence [40, 69].
CD4+ T Cell Recovery During Antiretroviral Therapy
Though ART suppresses ongoing HIV replication in the periphery to undetectable levels,
up to 30% of ART-treated individuals with chronic HIV infection fail to achieve CD4+ T cell
counts to a normal level (> 500 cells/mm3) [70]. This phenomenon has been referred to in the
literature as immunologic non-response, CD4+ T cell response, and immuno-virological
discordance, and it has been associated with factors including older age, viral hepatitis coinfection,
lower nadir CD4+ T cell count, longer duration of untreated HIV infection, and worse morbidity
and mortality [70-74]. Hereafter referred to as poor CD4 recovery, this phenomenon is more likely
to occur in patients who initiate ART late in the course of infection, often associating with a low
CD4 nadir [71, 75]. As mentioned earlier, in the initial stages of HIV infection, there is a rapid and
severe depletion of circulating CD4+ T cells, followed by a spontaneous but temporary recovery
[48]. Initiation of ART within four months of HIV infection to coincide with this temporary
recovery period has been associated with improved CD4 recovery [71, 76].
Although it is uncommon to identify individuals during the narrow window of AHI, the
RV254/SEARCH 010 study follows a cohort of individuals with AHI in Thailand who are
identified and begin ART soon after HIV infection. As described earlier, initiation of ART during
AHI partially resolves systemic inflammation and reduces the viral reservoir [53, 56].
Furthermore, initiation of ART during Fiebig stage I results in improved immunological
reconstitution compared to Fiebig stages II-IV [53].
Whether identifying and treating HIV at the earliest stages of infection (within one month)
reduces the frequency of clinical immunologic non-response is not known, though improved CD4
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recovery has been described in ART initiation within four to six months of infection or
seroconversion [71, 76, 77]. Whether HIV-associated neuroinflammation or HIV-associated
neurocognitive or affective symptoms are associated with poor CD4 recovery have yet to be
examined.
CSF HIV Escape During Antiretroviral Therapy
In early HIV infection, central nervous system (CNS) infection can be detected by the
presence of HIV RNA in the cerebrospinal fluid (CSF) as early as eight days after infection [55,
78]. Indeed, more than half of RV254 participants with AHI reported neurological symptoms
within 12 weeks after diagnosis, with half of those occurring before diagnosis and ART initiation
[79]. Thus, the CNS is affected early in HIV infection, both virologically and clinically.
Interestingly, virological dynamics between plasma and CSF show that in AHI, CSF HIV RNA is
consistently lower than concurrent plasma HIV RNA [55]. Given this and the proposed mechanism
of immune cell trafficking that may introduce HIV into the CNS, it is likely that CSF HIV RNA
has a delayed appearance behind that in plasma [40].
As discussed in the prior section “Acute HIV Infection”, markers of immune activation
and inflammation appear in the CNS in AHI [55]. Importantly, there are neuroimaging findings,
specifically magnetic resonance spectroscopy, that are consistent with early CNS inflammation,
including elevated choline/creatinine that likely represents immune cell activation [55]. However,
neurofilament light chain (NFL) in CSF, a marker for neuronal injury, was not elevated in AHI
[80]. It is thus possible that in AHI, the CNS is infected through trafficking of infected immune
cells or perhaps viral seeding across a compromised blood-brain barrier, resulting in localized
neuroinflammation but without detectable neuronal injury as long as ART is promptly started.
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Rapid initiation of ART suppresses HIV replication in the CNS and reverses neuroinflammation
[40, 58].
Importantly, the CNS may continue to be affected uniquely in the phenomenon of CSF
escape, in which viral presence is undetectable in the periphery due to ART suppression but is
detectable in CSF. Initially thought to be rare, one study has suggested an incidence rate of up to
10% of individuals with CSF escape [81]. An area of active investigation, only recently have there
been international consensus guidelines to provide a clearer definition, which are reproduced in
Table 2 [82]. CSF escape may vary from asymptomatic to symptomatic, as CSF HIV RNA may
be detected only incidentally via unrelated lumbar puncture. However, lumbar puncture may also
be indicated in the work-up of new neurological symptoms in an ART-adherent, previously wellcontrolled patient with HIV [83]. Peluso et al presented a case series of ten patients with
symptomatic CSF escape, wherein new neurologic symptoms (sensory, motor, and/or cognitive)
prompted lumbar puncture and, for some, neuroimaging and CSF resistance testing. All patients
had CSF pleocytosis or elevated CSF protein, and among those who had the studies conducted,
most had magnetic resonance imaging (MRI) findings (7 of 8) and CSF resistance mutations (6 of
7). Optimizing the ART regimen clinically improved eight of nine patients [84]. Thus, CSF escape
encompasses a clinical phenomenon that can have symptomatic impact in some patients, which
may also be resolvable by treatment optimization. In at least some patients with CSF escape, there
is evidence of neuroinflammation. Additionally, another potential driver of CSF escape is
compartmentalized drug resistance secondary to sub-therapeutic levels of antiretrovirals in the
CSF, given the findings of this case series.
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Table 2. Recommended guidelines for definitions of cerebrospinal fluid escape, from the
Second Global HIV CSF Escape Consortium in 2017
1. When plasma HIV RNA is suppressed, the presence of quantifiable HIV RNA in the
cerebrospinal fluid at any level should be considered cerebrospinal fluid HIV RNA escape
2. When plasma HIV RNA is detectable, cerebrospinal fluid HIV RNA greater then plasma
HIV RNA, at any level, should be considered cerebrospinal fluid HIV RNA escape
3. Defining symptomatic versus asymptomatic cerebrospinal fluid HIV RNA escape should be
based on patient symptomatology
4. Cerebrospinal fluid HIV escape should be actively managed in
symptomatic cases
Reproduced from [82].

CSF escape may also be secondary to a superimposed neuroinflammatory or
neuroinfectious condition [83]. Cases have been described of CSF escape in the context of
neurosyphilis, varicella zoster virus meningitis, and neuroborreliosis [85-87]. The possibility of
secondary CSF escape from superimposed neuroinflammation makes it difficult to reconcile
whether inflammation drives CSF escape via increased immune cell trafficking or blood-brain
barrier disruption, or whether CSF escape can drive a localized neuroinflammatory response to
localized viral replication.
One concern for CSF HIV escape during ART is that even low-level HIV replication in
CSF has been shown to associate with markers of immune activation and CNS injury. Spudich et
al characterized a subset of participants in primary HIV infection with CSF HIV RNA < 100
copies/mL who had increased neuroinflammation, as measured by CSF white blood cells (WBC),
neopterin, and CXCL10, compared to HIV-negative controls [88]. In a group of patients with < 40
copies/mL of HIV RNA in both plasma and CSF by standard assays, ultrasensitive assays found
that those with low-level CSF HIV RNA tended to have higher CSF neopterin [89], even with
years of suppressive ART. Similarly, low-level detection of CSF HIV associates with
compromised blood-brain barrier integrity and decreased executive function [90]. Thus, while
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frank CSF escape (e.g. > 100 copies/mL) may result in new neurological impairment, there is also
concern for subclinical or low-level CSF escape that is also pathological.
Finally, one last concern for CSF HIV escape is whether it indicates the presence or longterm persistence of a CNS reservoir [83]. This is especially relevant in the discussion and progress
towards achieving ART-free HIV remission, as the CNS reservoir remains an important target.
One important point to consider is that persistent CSF escape most likely points to HIV replication
from CNS resident cells, i.e. a reservoir. However, not all cases of CSF escape are persistent;
indeed some appear to be episodic [91], though this is difficult to know for certain given the paucity
of longitudinal CSF data [41]. Episodic CSF escape, otherwise called CSF HIV viral blips, could
stem from CNS reservoirs, but could also be explained by transient immune cell trafficking into
the CNS that supports local viral replication [41]. Joseph et al investigated cases of CSF escape
using deep sequencing, identifying one case of a macrophage-tropic, partially drug-resistant,
genetically diverse escape population likely to stem from CNS reservoirs, and two cases of T celltropic, genetically homogenous escape populations likely to stem from immune cell trafficking
and transient clonal expansion [92].
Given the potential significance of CSF escape for ongoing inflammation and CNS injury
in the setting of peripheral ART suppression, as well as for pointing to a CNS HIV reservoir, it
remains unknown whether CSF escape can occur after identifying and treating AHI within the first
month of infection. Early ART in AHI appears to confer benefit in terms of mitigating
neuroinflammation and neuronal injury, as described above, but whether it confers a benefit in
terms of reducing events of CSF escape remains uncertain. Investigating this open question can
illuminate whether very early ART reduces CNS persistence of HIV infection [40].
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Statement of Purpose
This thesis encompasses two projects pertaining to immunological reconstitution and
CNS reservoirs in AHI: to investigate if poor CD4 recovery occurs (Project 1) and if CSF escape
occurs (Project 2) when ART is started during AHI. We identified pre-ART (baseline) and onART clinical and laboratory parameters associated with poor CD4 recovery, including systemic,
central nervous system (CNS), and coinfection factors known to associate with CD4 recovery in
chronic infection. We also identified clinical and laboratory factors associated with CSF escape
in treated AHI.

Methods
Study Participants
Individuals with AHI identified at the Thai Red Cross AIDS Research Centre (TRC-ARC)
in Bangkok were enrolled in the ongoing RV254/SEARCH010 study (clinicaltrials.gov
NCT00796146) [93]. The TRC-ARC is an anonymous voluntary HIV testing and counseling
center in Bangkok, Thailand. Clients are provided a unique identifier at their first visit, which is
used for all subsequent visits. Clients also fill out an optional demographic and risk-behavior
questionnaire. RV254/SEARCH010 is a study within TRC-ARC that identifies clients with Fiebig
stages I through V AHI, using paired 4th-generation HIV antigen/antibody immunoassay and
nucleic acid testing (NAT), and offers immediate ART.
Nonreactive 4th-generation immunoassays had their samples pooled for qualitative NAT
screening. Pooled samples with reactive NAT testing were deconstructed, and individual samples
were re-tested to identify HIV-positive samples. HIV-positive samples were tested by quantitative
NAT, 3rd- and 2nd-generation immunoassays, and p24 Western blots; clients were contacted and
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asked to enroll in the study. Clients with reactive 4th-generation immunoassay, nonreactive 3rdgeneration immunoassay or nonreactive 2nd-generation immunoassay, and p24 Western blot
negative or indeterminate were contacted and requested to enroll in the study. All samples were
tested within 24 hours to quickly identify AHI [93]. One participant who was enrolled as Fiebig V
was subsequently reclassified to Fiebig VI based on new assay thresholds and was retained in the
study.
Duration of infection was estimated based on dates of exposure in the past 30 days.
Participants voluntarily documented exposure events within the past 30 days. Exposure events
were stratified according to no risk (no exchange of bodily fluids, non-insertive sex, or contact of
bodily fluids with intact skin), low risk (receptive oral sex without ejaculation, insertive oral sex,
or exposure of mucous membranes to bodily fluids), medium risk (anal or vaginal sex with condom
use regardless of HIV serostatus, receptive condom-less oral sex with male partner with either
unknown HIV serostatus or positive HIV serostatus with suppressed viral load), or high risk (anal
or vaginal sex without condom use, receptive condom-less oral sex with male HIV-positive partner
with detectable or unknown viral load, or injection drug use). The HIV exposure date was
calculated as the mean date of all exposures in the highest risk category reported by the participant.
Exposure events within the past 30 to 60 days were considered only if the participant reported no
sexual activity within the past 30 days, or if the participant tested in Fiebig stages III-V and
reported high risk exposures in the past 30 to 60 days and lower risk exposures in the past 30 days.
Participants were offered immediate initiation of ART via an accompanying protocol
(clinicaltrials.gov NCT00796263). Standard first-line ART through 2016 included efavirenz plus
two nucleoside reverse transcriptase inhibitors. Efavirenz could be replaced by ritonavir-boosted
lopinavir or raltegravir for intolerance or resistance. A subset received a five-drug regimen that
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added raltegravir and maraviroc [94]. The majority were switched from efavirenz to dolutegravir
starting in 2017.
Participants underwent serial interviews, examinations, and phlebotomy, with optional
procedures. Clinical and laboratory assessments were performed at days 0, 2, 3, 5, 7, 10, and at
weeks 2, 4, 8, 12, 16, 20, 24, and every 12 weeks thereafter. Laboratory assessments included
CD4+ T cell count, CD8+ T cell count, HIV RNA, and complete blood count. Hepatitis B and C
serology testing was performed every 48 weeks. Infection with hepatitis B or C was confirmed
with plasma viral load testing. Additional laboratory assessments included biomarkers of
inflammation and immune activation, as listed below. Optional procedures included lumbar
puncture, brain MRI/MRS, sigmoid biopsy, leukapheresis, inguinal lymph node biopsy, and
genital secretions.
Optional lumbar punctures were obtained at study entry and at weeks 24, 96, and 240. CSF
studies included cell count, protein, glucose, and HIV RNA. The remaining cell-free CSF was
stored within six hours of collection at −80°C.
T1-weighted and T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI brain
scans were optionally obtained at study entry on the same 1.5T GE scanner, and were
independently interpreted by two neuroradiologists.
An optional neuropsychological testing battery was obtained at study entry and weeks 12,
24, and 96. It consisted of the Grooved Pegboard test in the nondominant hand (fine motor
function), Color Trails 1 and Trail Making A (psychomotor speed), and Color Trails 2 (executive
functioning/set-shifting). Raw neuropsychological testing results were standardized to healthy
Thai control participants from equivalent age and education strata to calculate z-scores [95]. A
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mean of z-scores was computed (NPZ-4) for an overall metric of neuropsychological testing
performance.
Participants completed the Thai version of the Hospital Anxiety and Depression Scale
(HADS), a 14-item scale with anxiety and depression subscales of 7 items each. Each item is
scored from 0 to 3, with a total score range of 0 to 21 per subscale.
All participants provided written informed consent prior to enrollment in the cohort. The
research protocol was approved by institutional review boards at Chulalongkorn University
Hospital, Yale School of Medicine, UCSF, and the Armed Forces Research Institute for Medical
Sciences.
Project 1 included all participants who initiated ART between April 2009 and April 2016
with at least 48 weeks of documented HIV-RNA < 50 copies/mL, regardless of time to
suppression. Eligible participants were stratified by latest CD4+ T cell count to suboptimal
recovery (<350 cells/mm3), intermediate recovery (350-499 cells/mm3), and complete recovery
(≥500 cells/mm3), in agreement with and for appropriate comparison to prior studies of CD4
recovery in chronic HIV [70]. None of the participants enrolled in analytic treatment interruption
or interventional substudies before the latest follow-up visit used in the analysis.
Project 2 included all participants who initiated ART between April 2009 and April 2019
with paired blood and CSF sampling in at least one visit at study enrollment (baseline), week 24,
or week 96. CSF escape was defined as paired CSF HIV RNA greater than plasma HIV RNA at
week 24 or week 96, as per recent international consensus definitions [82].
Sampling and Laboratory Testing
For Project 1, clinical and laboratory parameters were assessed at baseline and latest study
visit. Blood and CSF markers of immune activation, neuropsychological (NP) testing, and mood
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assessments were examined at a standardized interval of 96 weeks after starting ART. CD4+ T
cell count was assessed at all available study visits to investigate longitudinal trends. For Project
2, clinical and laboratory parameters were assessed at baseline, week 24, and week 96.
CD4+ T cell count was measured by single- and dual-platform flow cytometry (BectonDickinson). HIV RNA in plasma was performed using the COBAS AMPLICOR HIV-1 Monitor
Test v1.5 or COBAS Taqman HIV-1 Test v2.0 (Roche Molecular Systems). Lower limit of
quantification for plasma HIV RNA was 50 and 20 copies/mL, respectively, depending on the
platform used. CSF samples were diluted fourfold for volume requirements for detection of HIV
RNA, with a lower limit of quantification at 80 copies/mL using the Taqman platform.
Plasma soluble CD14 (sCD14), intestinal fatty acid binding protein (I-FABP) (R&D
Systems), and hyaluronic acid (Corgenix) were measured by ELISA. C-reactive protein was
measured by electrochemiluminescence assay (Meso Scale Discovery). D-dimer was measured by
enzyme-linked fluorescent assay (bioMerieux). Tumor necrosis factor-alpha (TNF-alpha) and
high-sensitivity interleukin 6 (IL-6) were measured by the Luminex platform (Millipore). All
assays for biomarkers were performed in duplicate on cryopreserved acid citrate dextrose plasma
for research purposes only following a single thaw with the exception of I-FABP (two thaws).
Anti-hepatitis C antibodies, hepatitis B surface antigen (HBsAg), and anti-HBsAg antibodies were
measured by chemiluminescent microparticle immunoassay (Abbott). Syphilis testing was
measured by B VDRL Antigen BD Difco (Becton Dickinson), Macro-Vue RPR Card Tests
(Becton Dickinson), and Serodia TPPA (Fujirebio Diagnostics). CSF levels of neopterin were
measured by ELISA (GenWay Biotech).
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Statistical Analysis
Data were reported as median (interquartile range, IQR) values, except when otherwise
indicated. Comparisons between CD4 recovery groups were performed using the Mann-Whitney
U test or Kruskal-Wallis test for continuous variables, c2 test for categorical variables, and linear
regression for slope analyses. Slope analyses were performed by assessing CD4 change from
baseline to week 48 on ART. Multivariate logistic regression analyses were adjusted for baseline
CD4 count, baseline HIV-RNA, and duration on ART. Statistical tests were two-sided, and
differences were considered significant at p<0.05. Differences were considered suggestive of a
trend at p<0.10. Analyses were performed using SPSS Statistics (version 24; IBM), R (version
3.6.1; R Foundation for Statistical Computing), and Prism (version 7.0; GraphPad) software.
Author Contributions
This author conceived the study for Project 1 based on an identification of gaps in the
literature on CD4+ T cell recovery in the setting of very early ART initiation. The adviser assisted
with study design to investigate these questions in the RV254 cohort. The author and adviser
conceived the study for Project 2 based on prior work on CSF escape, which had not yet been
investigated in acute HIV infection. This author worked on-site at the Thai Red Cross AIDS
Research Centre in Bangkok, Thailand, in August 2019, to review clinical records, collect and
clean data, and perform statistical analyses. Collaborators participated in study coordination,
including study cohort oversight, research procedures including blood draw and lumbar puncture,
neuropsychological testing, laboratory testing, and data management. Assays were performed by
collaborators either locally in Bangkok or at research laboratories in Maryland. This author
performed all statistical analyses, apart from assistance provided by Suteeraporn Pinyakorn for
slope analyses in Project 1. A full list of collaborators is available in the Acknowledgments section.
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Results: Project 1
Study Participant Characteristics
During the RV254/SEARCH010 study period, 304 participants with AHI immediately
started ART and had documented viral load < 50 copies/mL for at least 48 weeks (Figure 1), of
whom 79 underwent optional CSF sampling. 96% of enrollees were Thai men, the majority men
who have sex with men. Median age was 26 years (range 18-57). ART was started at a median 19
days post-estimated infection (range 1-62). Median latest follow-up visit was at 144 weeks (range
60-420).
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Figure 1. Longitudinal HIV RNA of participants with acute HIV infection. Solid line
represents the proportion of participants with HIV RNA < 50 copies/mL at each follow-up study
visit week. Dotted line represents the total number of participants at each study visit week.

CD4+ T Cell Recovery After ART in Acute HIV
Of the 304 participants, the most recent CD4 count was <350 cells/mm3 (suboptimal
recovery) in 3.6%, 350-499 cells/mm3 (intermediate recovery) in 14.5%, and ³500 cells/mm3
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(complete recovery) in 81.9%. Viral load at enrollment, time from HIV transmission to ART
initiation, week of first documented viral suppression, and Fiebig stage at enrollment did not differ
between recovery groups (Table 3). Duration of ART was shortest in the intermediate recovery
group (median 120 weeks, IQR 84-192, p=0.03) but did not differ between suboptimal (156, 84180) and complete recovery groups (156, 108-216, p=0.5). Duration of ART was shorter in the
combined suboptimal and intermediate recovery group versus complete recovery (p=0.01).
CD4 counts of individuals in the three recovery groups were plotted at each study visit
week (Figure 2). Using slope analysis, mean (standard deviation) rates of recovery were 3.1 (3.4),
3.5 (2.1), and 5.5 (4.1) cells/mm3/week for suboptimal, intermediate, and complete recovery
groups, respectively. Recovery rate in intermediate recovery was significantly slower compared to
complete recovery (rate difference -2.0 cells/mm3/week, 95% confidence interval [CI] -3.3 to -0.8,
p=0.002). There was a trend of slower rate in suboptimal compared to complete recovery (rate
difference -2.4 cells/mm3/week, 95% CI -4.7 to 0.0, p=0.05). There was no difference between
suboptimal and intermediate recovery groups. Individuals were stratified into groups of low (<350
cells/mm3), medium (350-499 cells/mm3), and high (≥500 cells/mm3) baseline CD4 count, and
longitudinal CD4 counts within each group were plotted at each study visit week (Figure 3).
CD4 count differed by Fiebig stage at enrollment and was highest for Fiebig stage I at
enrollment (p<0.0001, Figure 4). CD4 count at latest study visit was not different by Fiebig stage
at enrollment. Change in CD4 count between baseline and latest study visit was different by Fiebig
stage at enrollment and was greatest for Fiebig stage II and least for Fiebig stage I at enrollment
(p<0.0001).
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Table 3. Characteristics of participants treated in acute HIV infection stratified by CD4
recovery group.
Characteristics
Suboptimal
Intermediate
Complete
pRecovery,
Recovery,
Recovery,
value
CD4<350, 350≤CD4<500
CD4≥500
(n=11)
(n=44)
(n=249)
Age, years (IQR)
23 (20-30)
26 (23-30)
26 (23-33)
0.3
Sex, male:female, n
11:0
44:0
237:12
0.3
Risk behavior, n (%)
WSM
0 (0)
0 (0)
12 (5)
MSW
1 (9)
3 (7)
9 (4)
0.4
MSM
10 (91)
41 (93)
228 (92)
Thai ethnicity, n (%)
Illicit drug use during HIV
exposure, n (%)
HIV-RNA at enrollment (log10
copies/mL), median (IQR)
Time to ART initiation (days),
median (IQR)
1st week of viral suppression,
median (IQR)
ART duration (weeks), median
(IQR)
Fiebig stage at enrollment, n
(%)
Stage I
Stage II
Stage III
Stage IV
Stage V

11 (100)

43 (98)

244 (98)

0.9

2 (18)

13 (30)

51 (21)

0.4

5.9 (5.4-7.3)

6.1 (5.4-6.9)

5.7 (5.2-6.6)

0.3

20 (14-23)

21 (15-28)

19 (15-26)

0.6

16 (8-24)

12 (8-24)

12 (8-24)

>0.9

156 (84-180)

120 (84-192)

156 (108-216)

0.03

2 (18)
4 (36)
5 (45)
0 (0)
0 (0)

5 (11)
9 (21)
22 (50)
6 (14)
2 (5)

44 (18)
71 (29)
90 (36)
26 (10)
18 (7)

0.2

Abbreviations: HIV, human immunodeficiency virus; WSM, women who have sex with men; MSW, men who
have sex with women; MSM, men who have sex with men; IQR, interquartile range.
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Figure 2. Longitudinal CD4+ T cell counts of participants with acute HIV infection according
to suboptimal, intermediate, and complete recovery groups. (A) Mean CD4+ T cell counts of
all participants (black) and by suboptimal (red), intermediate (green), and complete recovery (blue)
groups. Dotted black line represents the total number of participants across all recovery groups at
each study visit week. B-D, CD4+ T cell counts of participants in suboptimal (B), intermediate
(C), and complete (D) recovery groups. Solid lines represent the mean CD4+ T cell count at each
follow-up study visit week. Dashed lines represent the 95% confidence interval of CD4+ T cell
counts at each study visit week. Dotted black lines represent the total number of participants in
each respective recovery group at each study visit week. Confidence intervals for panels B-D tend
to increase over time due to the declining sample size of participants at each subsequent week of
follow-up visit.
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Figure 3. Longitudinal CD4+ T cell counts of participants with acute HIV infection according
to low, medium, and high baseline CD4 count. (A) Mean CD4+ T cell counts of all participants
(black) and by low (red, baseline CD4 < 350 cells/mm3), medium (green, baseline CD4 350-499
cells/mm3), and high (blue, baseline CD4 ≥ 500 cells/mm3) baseline CD4 count. Dotted black line
represents the total number of participants at each study visit week. B-D, CD4+ T cell counts of
participants with low (B), medium (C), and high (D) baseline CD4 count. Solid lines represent the
mean CD4+ T cell count at each follow-up study visit week. Dashed lines represent the 95%
confidence interval of CD4+ T cell counts at each study visit week. Dotted black lines represent
the total number of participants in each respective group at each study visit week. Confidence
intervals for panels B-D tend to increase over time due to the declining sample size of participants
at each subsequent week of follow-up visit.
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Figure 4. CD4+ T cell count by Fiebig stage at enrollment. Violin plots of CD4 count at baseline
(A) and at latest study visit (B) by Fiebig stage at enrollment. (C) Violin plot of change in CD4
count between baseline and latest study visit by Fiebig stage at enrollment. Comparison between
groups by Kruskal-Wallis test. **** indicates p<0.0001, ns indicates not statistically significant.

Baseline Pre-ART Predictors of CD4 Recovery After ART
At baseline, CD4 and absolute lymphocyte counts were lower in participants with
suboptimal compared to complete recovery (CD4 count: median 265 vs 411 cells/mm3, p=0.002,
Table 4). CD8 count, CD4/CD8 ratio, hemoglobin, and platelet count at baseline were not different
between suboptimal and complete recovery.
Given the small size of the suboptimal recovery group and the similar CD4 trajectories of
the suboptimal and intermediate recovery groups, we combined these two groups and compared
baseline predictors with complete recovery. CD4/CD8 ratio and CD4+ T cell, total WBC, absolute
lymphocyte, absolute monocyte, and platelet counts were lower in the combined group compared
to the complete recovery group at baseline. Intestinal fatty acid binding protein (I-FABP) was
lower in the combined group compared to complete recovery. Other markers of inflammation were
similar between these groups (Table 4).
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Table 4. Pre-ART baseline predictors of CD4 recovery.
Suboptimal &
Intermediate
Recovery,
CD4<500 (n=55)
275 (214-371)

Complete
Recovery,
CD4≥500 (n=249)

p-value†

p-value‡

CD4 count (cells/mm3)

Suboptimal
Recovery,
CD4<350
(n=11)
265 (91-371)

411 (303-533)

0.002

< 0.001

CD8 count (cells/mm3)

412 (228-575)

448 (298-847)

512 (339-854)

0.09

0.4

0.67 (0.37-0.94)

0.66 (0.35-0.87)

0.81 (0.47-1.2)

0.4

0.003

4.5 (3-5.6)

4.7 (4.0-5.6)

5.5 (4.4-7.0)

0.03

0.003

Absolute neutrophil count (×
103 cells/mm3)

2.84 (1.56-3.52)

2.90 (2.24-3.60)

3.13 (2.18-4.22)

0.3

0.2

Absolute lymphocyte count
(× 103 cells/mm3)

1.06 (0.69-1.48)

1.18 (0.93-1.91)

1.58 (1.21-2.10)

0.003

< 0.001

Monocyte count (× 103
cells/mm3)

0.38 (0.28-0.63)

0.40 (0.31-0.52)

0.52 (0.42-0.66)

0.1

< 0.001

Eosinophil count (× 103
cells/mm3)

0.045 (0.0000.308)

0.023 (0.0120.049)

0.038 (0.018-0.082)

0.9

0.09

15 (14-16)
215 (167-233)

15 (14-16)
215 (180-248)

15 (14-16)
234 (188-296)

0.2
0.1

0.2
0.01

sCD14 (µg/L)

-

1.3 (1.1-2.3)a

1.6 (1.1-1.9)b

-

0.9

IL-6 (pg/mL)

-

0.6 (0.4-1.4)c

0.5 (0.3-0.9)d

-

0.3

Hyaluronic acid (ng/mL)

-

17.6 (9.7-30.2)a

18.0 (9.0-32.4)b

-

0.96

Intestinal fatty acid binding
protein (pg/mL)

-

738 (343-944)a

1044 (637-1559)b

-

0.045

C-reactive protein (mg/L)

-

2.1 (0.5-4.2)a

1.3 (0.7-3.4)b

-

0.96

TNF-alpha (pg/mL)

-

1.3 (0.8-2.1)c

1.2 (0.7-2.2)d

-

0.9

D-dimer (ng/mL)

-

357 (283-473)a

266 (173-435)b

-

0.3

Pre-ART Baseline Predictors

CD4/CD8 ratio
WBC count (× 103
cells/mm3)

Hemoglobin (g/dL)
Platelet count (× 103/mm3)

Median (IQR).
Abbreviations: CD4, CD4+ T cell; CD8, CD8+ T cell; WBC, white blood cell; sCD14, soluble CD14; IL-6,
interleukin-6; TNF-alpha, tumor necrosis factor alpha.
†
P-value is for suboptimal recovery vs complete recovery.
‡
P-value is for combined suboptimal & intermediate recovery vs complete recovery.
a
n=8; bn=63; cn=16; dn=118

27
CSF sample results for suboptimal (CSF n=3) and intermediate (CSF n=7) recovery groups
were also combined for comparison to complete recovery (CSF n=69). CSF viral load, WBC count,
protein, and glucose were not different between the combined and complete recovery groups.
Baseline CSF neopterin trended in elevation in the combined group (n=10) compared to the
complete recovery group (n=69, median 2938 vs. 1623 pg/mL, p=0.05, Table 5). Suboptimal
versus complete recovery groups did not differ on neuropsychological tests (Color Trails 1, Color
Trails 2, Trail Making A, Grooved Pegboard) or psychiatric indices (Patient Health Questionnaire)
at baseline (Table 6). Markers for co-infection or exposure to hepatitis B virus, hepatitis C virus,
and syphilis at baseline were not associated with CD4 recovery (Table 6).
Table 5. Pre-ART baseline predictors of CD4 recovery, measured in CSF.
Pre-ART Baseline
Suboptimal & Intermediate
Complete Recovery,
Predictors in CSF
Recovery, CD4<500
CD4≥500 (n=69)
(n=10)
CSF HIV RNA (log10
3.8 (2.9-4.2)
3.0 (2.0-4.1)
copies/mL)
CSF WBC count
0 (0-0)
0 (0-0)
(cells/mm3)
CSF protein (mg/dL)
38 (26-41)
29 (25-35)
CSF glucose (mg/dL)
CSF neopterin (pg/mL)

p-value‡
0.3
0.7
0.3

62 (58-66)

61 (57-66)

0.7

2938 (2069-5310)

1623 (958-3140)

0.05

Median (IQR).
Abbreviations: ART, anti-retroviral therapy; CSF, cerebrospinal fluid; WBC, white blood cell.
‡
P-value is for combined suboptimal & intermediate recovery vs complete recovery.
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Table 6. Additional pre-ART baseline predictors of CD4 recovery.
Pre-ART Baseline
Suboptimal Suboptimal &
Complete
Predictors
Recovery,
Intermediate
Recovery,
CD4<350
Recovery,
CD4≥500
CD4<500
Positive anti-HCV,
0/10 (0)
1/54 (2)
2/248 (1)
n (%)
Positive anti-HBs,
5/11 (45)
28/54 (52)
133/249 (53)
n (%)
Positive HBsAg, n
1/11 (9)
3/55 (5)
15/249 (6)
(%)
Reactive VDRL, n
2/10 (20)
7/54 (13)
30/249 (12)
(%)
NPZ-4 score
0.007 (-0.7 –
-0.002 (-0.5 –
-0.02 (-0.6 –
0.1)
0.4)
0.6)
n=11
n=50
n=216
Total PHQ score
14 (7 – 16)
12 (7 – 15)
9 (6 – 14)
n=11
n=50
n=216

p-value†

p-value‡

0.8

0.5

0.6

0.8

0.7

0.9

0.5

0.9

0.4

0.8

0.2

0.09

Abbreviations: ART, anti-retroviral therapy; HCV, hepatitis C virus; anti-HBs, hepatitis B surface antibody;
HBsAg, hepatitis B surface antigen; VDRL, Venereal Disease Research Laboratory test; NPZ-4,
neuropsychological test z-score in four domains (Color Trails 1, Color Trails 2, Trail Making A, Grooved
Pegboard); PHQ, Patient Health Questionnaire.
†
P-value is for suboptimal recovery vs complete recovery.
‡
P-value is for combined suboptimal & intermediate recovery vs complete recovery.

On-ART Factors Associated with CD4 Recovery
The ART regimen initiated at AHI did not predict CD4 recovery (Table 7). By the time of
most recent study visit, 113 of the 304 participants (37%) were switched to a dolutegravircontaining regimen after a median (IQR) duration of ART of 145 (107-212) weeks. There was no
association between switch to dolutegravir and CD4 recovery (not shown).
As mentioned earlier, assessment of on-ART factors was performed at the latest study visit
week for each participant, which was at median 144 weeks (range 60-420). Some assays and
testing, including blood and CSF markers of immune activation, neuropsychological (NP) testing,
and mood assessments, were only performed at standardized intervals of 24 and 96 weeks. For
these, we focused on assessments at 96 weeks due to our interest in longer term CD4 recovery.
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Table 7. Initial ART regimen stratified by CD4 recovery group.
Suboptimal
Recovery,
CD4<350
Intermediate
Recovery,
350≤CD4<500
Complete
Recovery,
CD4≥500
Total

2NRTI/LPV/r

2NRTI/EFV

2NRTI/RAL

2NRTI/MVC/RAL

2NRTI/EFV/MVC/RAL

Total

0

8

0

1

2

11

0

29

0

0

15

44

1

187

1

0

60

249

1

224

1

1

77

304

Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; LPV, lopinavir; r, ritonavir; EFV, efavirenz; RAL,
raltegravir; MVC, maraviroc.
Fisher’s exact test, p=0.1.

On ART, CD8+ T cell count and CD4/CD8 ratio were lower in suboptimal compared to
complete recovery (median 318 vs 621 cells/mm3, IQR 279-628 vs 490-843, p=0.001 and median
1.05 vs 1.18, IQR 0.47-1.20 vs 0.91-1.48, p=0.047, respectively) (Table 8). Additionally,
hemoglobin was higher in suboptimal compared to complete recovery. Platelets were diminished
in the suboptimal recovery group.
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Table 8. On-ART variables associated with CD4 recovery.
Suboptimal
Recovery,
CD4<350
(n=11)
318 (279-628)

Suboptimal &
Intermediate
Recovery,
CD4<500 (n=55)
460 (359-600)

Complete
Recovery,
CD4≥500 (n=249)

p-value†

p-value‡

621 (490-843)

0.001

< 0.001

CD4/CD8 ratio

1.05 (0.47-1.20)

0.95 (0.76-1.16)

1.18 (0.91-1.48)

0.047

< 0.001

WBC count (× 103
cells/mm3)

4.88 (4.68-6.25)

4.99 (4.36-5.74)

6.13 (5.34-7.27)

0.02

< 0.001

Absolute neutrophil count
(× 103 cells/mm3)

3.37 (2.52-4.45)

2.92 (2.27-3.57)

3.23 (2.48-4.21)

0.9

0.07

Absolute lymphocyte count
(× 103 cells/mm3)

0.99 (0.91-1.40)

1.46 (1.24-1.67)

2.19 (1.85-2.48)

2 × 10-7

< 0.001

Monocyte count (× 103
cells/mm3)

0.41 (0.36-0.64)

0.41 (0.35-0.51)

0.51 (0.40-0.62)

0.3

0.001

Eosinophil count (× 103
cells/mm3)

0.13 (0.09-0.19)

0.13 (0.09-0.20)

0.13 (0.08-0.24)

1.0

0.7

Hemoglobin (g/dL)

15.5 (14.5-16.4)

15.1 (14.4-15.8)

14.7 (14.0-15.6)

0.02

0.04

223 (185-283)

252 (218-277)

273 (237-313)

0.03

0.002

sCD14 at week 96 (µg/L)

-

1.7 (1.6-1.8)g

1.1 (1.0-1.2)h

-

0.008

IL-6 at week 96 (pg/mL)

-

0.13 (0.11-0.56)i

0.56 (0.14-0.97)j

-

0.04

Hyaluronic acid at week 96
(ng/mL)

-

15.1 (13.6-21.9)g

11.8 (9.0-18.9)h

-

0.4

Intestinal fatty acid binding
protein at week 96 (pg/mL)

-

1533 (1212-2058)g

2953 (1366-3823)h

-

0.3

C-reactive protein (mg/L)

-

0.22 (0.19-0.54)g

0.49 (0.19-1.08)h

-

0.7

TNF-alpha (pg/mL)

-

0.93 (0.40-16.13)i

1.61 (0.25-4.28)j

-

0.6

D-dimer (ng/mL)

-

190 (179-401)g

138 (102-256)h

-

0.3

On-ART Variables

CD8 count

Platelet count (× 103/mm3)

Median (IQR). Measurements were performed at latest study visit unless otherwise indicated.
Abbreviations: CD4, CD4+ T cell; CD8, CD8+ T cell; WBC, white blood cell; sCD14, soluble CD14; IL-6,
interleukin-6; TNF-alpha, tumor necrosis factor alpha.
†
P-value is for suboptimal recovery vs complete recovery.
‡
P-value is for combined suboptimal & intermediate recovery vs complete recovery.
a
n=23; bn=99; cn=22; dn=23; en=97; fn=98; gn=3; hn=25; in=8; jn=66
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After combining suboptimal and intermediate recovery groups, we identified on-ART
factors that differed between the combined and complete recovery groups (Table 8). Consistent
with the differences between suboptimal and complete recovery, CD8 count, CD4/CD8 ratio, and
WBC count were lower in the combined group compared to complete recovery. On-ART
hemoglobin was higher in the combined group, and platelet count was lower. Absolute lymphocyte
and monocyte counts were lower in the combined group. Serum sCD14 at week 96 was elevated
and IL-6 was lower in the combined group.
Optional CSF sample size during ART was too small to assess associations between
neuroinflammatory markers and CD4 recovery. Suboptimal and complete recovery did not differ
in neuropsychological test performance or psychiatric indices at 96 weeks of ART (Table 9). On
ART, markers for co-infection or exposure to hepatitis B virus, hepatitis C virus, and syphilis were
not associated with CD4 recovery (Table 9).
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Table 9. Additional on-ART variables associated with CD4 recovery.
Post-ART
Suboptimal Suboptimal &
Complete
Variables
Recovery,
Intermediate
Recovery,
CD4<350
Recovery,
CD4≥500
(n=11)
CD4<500
(n=249)
(n=55)
Positive anti-HCV,
0/2 (0)
1/15 (7)
1/49 (2)
n (%)
Positive anti-HBs,
2/2 (100)
14/16 (88)
42/50 (84)
n (%)
Positive HBsAg, n
0/2 (0)
1/16 (6)
8/49 (16)
(%)
Reactive VDRL, n
0/1 (0)
4/9 (44)
16/40 (40)
(%)
NPZ-4 score at
0.6 (-0.04 –
0.5 (-0.04 –
0.5 (0.03 – 1)
week 96
0.8)
0.9)
n=183
n=7
n=33
Total PHQ score at
5 (1 – 8)
4 (1 – 8)
5 (2 – 8)
week 96
n=7
n=33
n=183

p-value†

p-value‡

0.8

0.4

0.5

0.7

0.5

0.3

0.4

0.8

0.6

0.6

0.9

0.4

Abbreviations: ART, anti-retroviral therapy; HCV, hepatitis C virus; anti-HBs, hepatitis B surface antibody;
HBsAg, hepatitis B surface antigen; VDRL, Venereal Disease Research Laboratory test; NPZ-4,
neuropsychological test z-score in four domains (Color Trails 1, Color Trails 2, Trail Making A, Grooved
Pegboard); PHQ, Patient Health Questionnaire.
†
P-value is for suboptimal recovery vs complete recovery.
‡
P-value is for combined suboptimal & intermediate recovery vs complete recovery.

Independent Effect of Pre- and On-ART Factors on CD4 Recovery
We used a multivariate logistic regression model to adjust for duration of ART, baseline
HIV-RNA, and baseline CD4 count (Table 10). After adjustment, participants with baseline
CD4/CD8 ratio < 1 were more likely to have poor CD4 recovery < 500 cells/mm3 (odds ratio [OR]
3.2, 95% confidence interval [CI] 1.4-8.4, p=0.01). Participants with baseline I-FABP < 1000
pg/mL were more likely to have poor CD4 recovery (OR 13.4, 95% CI 1.9-276.4, p=0.02). Those
with baseline CSF neopterin > 1600 pg/mL had no different odds for poor CD4 recovery after
adjustment (OR 2.4, 95% CI 0.2-57.5, p=0.5). Participants with baseline platelet count < 300,000
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per mm3 were more likely to have poor CD4 recovery after adjustment (OR 3.5, 95% CI 1.2-15.3,
p=0.04).
After adjustment, odds of poor CD4 recovery were higher in participants with on-ART
CD4/CD8 ratio < 1 (OR 2.4, 95% CI 1.3-4.6, p=0.007), CD8 count < 500 cells/mm3 (OR 3.1, 95%
CI 1.6-6.0, p=0.0005), hemoglobin > 14.8 mg/dL (OR 2.0, 95% CI 1.0-4.0, p=0.04), and platelet
count < 300,000 per mm3 (OR 3.6, 95% CI 1.4-11.1, p=0.01). Participants with sCD14 > 1.8 µg/L
had no different odds for poor CD4 recovery (p>0.9). Participants with IL-6 < 0.2 pg/mL were
more likely to have poor CD4 recovery after adjustment (OR 6.2, 95% CI 1.2-47.4, p=0.04).
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Table 10. Factors Associated with CD4 Recovery < 500 cells/mm3
Univariate
Multivariate
Characteristic
OR (95% CI)
p-value
OR (95% CI)
p-value
Baseline CD4 count
< 0.001
<350 cells/mm3
7.7 (2.9-26.4)
350-499 cells/mm3
2.5 (0.8-9.3)
≥500 cells/mm3
1 (ref)
ART duration
0.02
48-119 weeks
1.7 (0.9-3.4)
120-155 weeks
0.9 (0.4-2.0)
≥156 weeks
1 (ref)
Baseline HIV-RNA
0.2
6
3
<10 copies/mm
1 (ref)
≥106 copies/mm3
1.7 (1.0-3.1)
Baseline CD4/CD8 ratio
0.002
0.01
<1
3.4 (1.6-8.6)
3.2 (1.4-8.4)
≥1
1 (ref)
1 (ref)
Baseline I-FABP
0.07
0.02
<1000 pg/mL
8.8 (1.4-168.7)
13.4 (1.9-276.4)
≥1000 pg/mL
1 (ref)
1 (ref)
Baseline CSF neopterin
0.3
0.5
<1600 pg/mL
1 (ref)
1 (ref)
≥1600 pg/mL
8.7 (1.5-165.7)
2.4 (0.2-57.5)
Baseline platelet count
0.01
0.04
<300,000 per mm3
4.7 (1.6-19.8)
3.5 (1.2-15.3)
≥300,000 per mm3
1 (ref)
1 (ref)
On-ART CD4/CD8 ratio
< 0.001
0.007
<1
2.7 (1.5-5.0)
2.4 (1.3-4.6)
≥1
1 (ref)
1 (ref)
On-ART CD8 count
< 0.001
< 0.001
<500 cells/mm3
3.2 (1.8-5.9)
3.1 (1.6-6.0)
≥500 cells/mm3
1 (ref)
1 (ref)
On-ART hemoglobin
0.02
0.04
<14.8 mg/dL
1 (ref)
1 (ref)
≥14.8 mg/dL
2.0 (1.1-3.9)
2.0 (1.0-4.0)
On-ART platelet count
0.002
0.01
3
<300,000/mm
3.7 (1.5-10.9)
3.6 (1.4-11.1)
≥300,000/mm3
1 (ref)
1 (ref)
sCD14 at week 96
0.03
1.0
<1.8 µg/L
1 (ref)
≥1.8 µg/L
12 (0.4-406.0)
IL-6 at week 96
0.1
0.04
<0.2 pg/mL
6.9 (1.4-50.0)
6.2 (1.2-47.4)
≥0.2 pg/mL
1 (ref)
1 (ref)
Multivariate models were adjusted for duration of ART, baseline HIV-RNA, and baseline CD4 count.
Abbreviations: CI, confidence interval; OR, odds ratio.
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Results: Project 2
Study Participant Characteristics
During the RV254/SEARCH010 study period, 204 participants with AHI immediately
started ART and had paired blood and CSF sampling in at least one visit at baseline, week 24, or
week 96. 98% of enrollees were Thai men, the majority men who have sex with men. Median
age was 26 years (range 18-60). At enrollment, participants were mostly in Fiebig stage III, with
median CD4+ T cell count 386 cells/mm3 (range 91-1302) and median plasma HIV RNA 5.87
log10 copies/mL (range 2.43-7.89). ART was started at a median 19 days post-estimated infection
(range 3-49).
At baseline, 126 of 165 participants (76%) had quantifiable CSF HIV RNA with median
CSF HIV RNA 3.13 log10 copies/mL (range <1.90-6.61). There were no cases where plasma
HIV RNA exceeded the paired CSF HIV RNA level. At week 24, of 90 available participants
with paired blood and CSF samples, two participants (2%) had quantifiable CSF HIV RNA. At
week 96, of 55 available participants with paired blood and CSF samples, one participant (2%)
had quantifiable CSF HIV RNA (Figure 5).
At week 24, of the four cases with detectable CSF HIV RNA, one met criteria for CSF
escape, with plasma HIV RNA < 50 copies/mL and CSF HIV RNA at 2.50 log10 copies/mL. At
week 96, the one case of detectable CSF HIV RNA did not meet criteria for CSF escape. All
other cases of detectable CSF HIV RNA were associated with plasma virological failure with
plasma HIV RNA greater than paired CSF HIV RNA.
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Table 11. Characteristics of participants treated in acute HIV infection with paired blood
and CSF samples at weeks 0, 24, and 96.
Characteristics
All participants
Baseline
Week 24
Week 96
(n=204)
(n=165)
(n=90)
(n=55)
Age at enrollment
26 (18-60)
26 (18-60)
27 (18-60)
28 (18-60)
(range)
Male, n (%)
199 (98)
160 (97)
86 (96)
53 (96)
Risk behavior, n (%)
WSM
5 (2)
5 (3)
4 (4)
2 (4)
MSW
7 (3)
6 (4)
1 (1)
2 (4)
MSM
192 (94)
154 (93)
85 (94)
51 (93)
Fiebig stage at
enrollment, n (%)
33 (16)
27 (16)
13 (14)
8 (15)
Stage I
47 (23)
37 (22)
20 (22)
11 (20)
Stage II
96 (47)
76 (46)
42 (47)
29 (53)
Stage III
19 (9)
17 (10)
10 (11)
3 (5)
Stage IV
8 (4)
7 (4)
4 (4)
3 (5)
Stage V
1 (0)
1 (1)
1 (1)
1 (2)
Stage VI
Time to ART
19 (3-49)
18 (3-49)
19 (7-49)
19 (9-42)
initiation (days),
median (range)
CD4+ T-cells,
386 (91-1302)† 389 (101-1302)
613 (291- 639 (320-1357)
3
cells/mm (range)
1464)
CD8+ T-cells,
517 (81-4556) 515 (102-4556)
575 (178- 628 (260-1575)
†
cells/mm3 (range)
1352)
Plasma HIV RNA,
log10 copies/mL,
(range)
Proportion of plasma
HIV RNA < 50
copies/mL, n (%)
CSF HIV RNA, log10
copies/mL, (range)
Proportion of CSF
HIV RNA < 80
copies/mL, n (%)
CSF viral escape, n
(%)

5.87 (2.43- 5.83 (2.43-7.89)
7.89) †

<1.30 (<1.305.44)

<1.30 (<1.304.42)

0 (0)

86 (96)

53 (96)

3.13 (<1.906.61)
39 (24)

<1.90 (<1.903.84)
88 (98)

<1.90 (<1.903.14)
54 (98)

1 (1)

0 (0)

0 (0) †
-

-

Abbreviations: HIV, human immunodeficiency virus; WSM, women who have sex with men; MSW, men who
have sex with women; MSM, men who have sex with men; CSF, cerebrospinal fluid.
†
At time of enrollment.
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Figure 5. Paired blood and CSF HIV RNA at weeks 0, 24, and 96. Medians and interquartile
ranges are indicated by black bars. Dashed lines represent paired blood and CSF HIV RNA from
participants who had either blood or CSF HIV RNA greater than the respective limit of
quantitation at week 24 or 96.

Clinical Course of CSF Escape During Treatment in Acute HIV Infection
Of 204 eligible participants, one participant at week 24 post-treatment initiation met
criteria for CSF escape. This is a 23-year-old male university student who identifies as bisexual,
who initially presented with acute retroviral syndrome. His past medical history includes
migraines and dengue fever. Three months before his presentation with acute HIV infection, he
was treated for chlamydia and gonorrhea infection. He denied alcohol, tobacco, and other drug
use. He was diagnosed with acute HIV infection in Fiebig stage IV at estimated 21 days post
infection and was immediately started on efavirenz, tenofovir, and emtricitabine. Plasma HIV
RNA and CD4+ T cell count responded rapidly to initiation of ART (Figure 6).
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Figure 6. Clinical measurements and neuropsychological testing for the case of CSF escape
in AHI. A) Longitudinal blood and CSF HIV RNA for the participant with CSF escape
identified at week 24. B) CD4+ and CD8+ T cell counts (left axis) and NPZ-4 score (right axis)
for the participant during treatment for acute HIV infection.
This participant had no study lumbar punctures performed other than that at week 24.
CSF white blood cell count was 4 cells/mm3, protein 30 mg/dL, and glucose 62 mg/dL. The
participant did not endorse any neurological symptoms at week 24. An MRI was performed at
this time, which showed a small nonspecific hyperintense focus in the right high frontal white
matter. The participant also underwent neuropsychological testing at weeks 0, 12, 24, and 96
(Figure 6). At week 12, the participant scored an NPZ-4 score of 1.76 standard deviations below
the reference population. At all other time points, NPZ-4 scores were unremarkable.
After 76 weeks on ART, this participant was transitioned to dolutegravir, abacavir, and
lamivudine per the study protocol, which was unrelated to the CSF findings from week 24.
At time of treatment initiation, the participant had a nonreactive VDRL. No VDRL was
performed at week 24. At 96 weeks on ART, the participant had a positive VDRL with a titer of
1:128.
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Discussion
Consistent with many other studies emerging from the RV254/SEARCH010 cohort of
participants with AHI, prompt treatment initiation in the earliest stages of HIV infection appears
to confer unique immunologic and virological benefits that mitigate the immune dysfunction and
reservoir establishment seen in treated chronic HIV infection. Not only does early treatment in
AHI reduce inflammation [56], it improves immunological reconstitution as measured by CD4+
T cell recovery. Early ART may also reduce the degree of HIV persistence specifically in the CNS
compartment, given the very low rate of CSF escape observed in tandem with a prior report of
normalization of neuroinflammation [58].
CD4+ T Cell Recovery in Acute HIV Infection
We found that suboptimal CD4 recovery occurs in a small subset of individuals despite
treatment in the earliest stages of AHI. Whereas 70-85% of individuals with chronic HIV infection
had CD4 recovery to >350 cells/mm3 after ART, we observed a larger proportion (96.4%) in AHI
[70]. A larger proportion of individuals were categorized as intermediate responders (CD4 count
350-499 cells/mm3) as compared to suboptimal responders (<350 cells/mm3). Prior work has
identified determinants of CD4 recovery in early seroconversion, though in the setting of delayed
ART initiation [76, 96]. To our knowledge, our study is the first to examine determinants of CD4
recovery with immediate ART initiation in the earliest stages of HIV infection. Furthermore, few
studies have identified determinants of CD4 recovery in chronic HIV infection in an Asian
population, and none in early seroconversion or primary HIV infection to our knowledge [97-99].
The degree of lymphatic tissue fibrosis has been shown to correlate with CD4 recovery
[19, 100]. As an indicator of a systemic profibrotic state, hyaluronic acid was lower in treated AHI
compared to treated chronic HIV infection, yet both remain elevated compared to HIV-uninfected
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controls [56]. Taken together, immediate ART initiation in AHI may limit the extent of lymphatic
tissue fibrosis compared to that seen in chronic HIV infection, which may explain the lower
proportion of suboptimal CD4 recovery in AHI.
When examining the suboptimal and intermediate recovery groups throughout the course
of treatment (Figure 2), CD4 count trajectories are similar. Additionally, though not apparent in
the aggregate analysis in Figure 2, some individuals with intermediate recovery appear to have
transient decreases in CD4 count below 350 cells/mm3, and may in fact sustain an overall CD4
response around or above the threshold of 350 cells/mm3. Thus, differences between the combined
suboptimal and intermediate recovery group versus complete recovery are more stark and reveal a
state of perturbed immunological recovery as compared to differences between suboptimal versus
intermediate recovery.
Poor CD4 recovery (< 500 cells/mm3) is associated with nadir CD4 count, and thus
increases from substantially low nadir may not be captured using an absolute threshold as a
definition of CD4 recovery. However, our slope analyses show that individuals with complete
recovery have a higher recovery rate over a fixed time interval of 48 weeks, indicating greater
absolute and relative increases in CD4 count. Other definitions of CD4 recovery have accounted
for low nadir, such as an increase of CD4 count ≥ 30% from baseline [101]. We used prior
definitions of CD4 recovery as absolute thresholds ≥ 350 or ≥ 500 cells/mm3 to allow for direct
comparison to results in chronic and primary HIV infection. Furthermore, absolute CD4+ T cell
count during treated HIV infection is a critical clinical measure for risk of opportunistic infections.
Consistent with a prior description of our cohort, individuals diagnosed and started on ART
at Fiebig stage I have a higher baseline CD4 count compared to stages II-IV, with normalization
of CD4 count after at least 48 weeks of treatment [53]. Individuals starting on ART at Fiebig stage
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I have a lower absolute CD4 increase compared to other stages, suggesting that CD4 decline to
nadir occurs at later Fiebig stages but is reversible with immediate ART initiation. Strategically
timing earlier ART initiation during an interval of CD4 recovery has been associated with better
long-term CD4 recovery [71, 72]. Conversely, ART initiation during an interval of CD4 decline is
associated with poor CD4 recovery [102], suggesting that strategic timing of early ART must
consider not only nadir CD4 count but also the dynamics of pre-ART CD4 recovery. However,
initiation of ART in Fiebig stages II-IV did not affect on-ART CD4 count, suggesting that ART
initiation in AHI does not need to be strategically timed and should be prompt.
Interestingly, our study showed that lower CD8 count during treatment, but not at baseline,
was associated with poor CD4 recovery, consistent with a previous report [103]. This may indicate
suppression of thymic output that has been observed to occur in the setting of poor CD4 recovery
[104]. However, another study found that higher baseline CD4 count and lower CD8 count were
independently associated with improved CD4 recovery [105]. The CD8 count may thus be
interpreted as an indicator of thymic output as well as of immune activation.
Poor CD4 recovery was independently associated with lower CD4/CD8 ratio both at
baseline and during treatment in AHI. Reduced CD4/CD8 ratio has been found to be a marker for
immune dysregulation and activation in the setting of HIV infection that has been associated with
an increased risk for non-AIDS related morbidity and mortality, including age-related
inflammation and cardiovascular disease [28, 106, 107]. Despite initiating ART at the earliest
possible stages of infection, low pre-ART CD4/CD8 ratio remained low on treatment and is a
predictor for poor CD4 recovery. For our group of poor responders treated during AHI, CD4/CD8
ratio at baseline was higher than in participants treated during chronic HIV infection, reflecting
less immune dysregulation at the earliest stages of infection [101, 105, 107]. Initiating ART during
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primary versus chronic HIV infection leads to a higher frequency of CD4/CD8 ratio > 1, with
higher CD4/CD8 ratio at baseline associated with a lower risk of poor CD4 recovery [72]. An
overall faster time to treatment initiation results in improved CD4/CD8 ratio [108]. Interestingly,
despite the rapid initiation of ART in early AHI, other markers of chronic inflammation persist in
the RV254/SEARCH010 cohort [56].
We analyzed markers for microbial translocation and systemic inflammation, finding
elevated sCD14 in suboptimal CD4 responders after treatment. However, sCD14 did not appear to
be independently associated with CD4 recovery after controlling for duration of ART, baseline
CD4 count, and baseline HIV-RNA. Some prior studies show increased sCD14, its ligand
lipopolysaccharide (LPS) [109], bacterial 16S ribosomal DNA [110], or neutrophil infiltration
[111] in poor compared to complete CD4 recovery, while others find no differences [101]. No
differences were detected in hyaluronic acid or in systemic inflammatory markers CRP, TNFalpha, and D-dimer [101]. Surprisingly, in our study IL-6 was elevated in complete recovery.
Elevated IL-6 has been associated with increased risk of HIV-associated opportunistic disease
[12]. Plasma I-FABP at baseline was higher in complete recovery, suggesting increased enterocyte
turnover, contrary to prior findings [111]. However, in our multivariate model, we report an odds
ratio for I-FABP with a large margin of error, suggesting this may be a spurious association.
Platelet counts were lower in poor compared to complete recovery both at baseline and
after ART, consistent with a prior study [112]. HIV-associated thrombocytopenia has several
possible mechanisms, including immune-mediated thrombocytopenia via immune complexes
composed of antibodies cross-reactive to HIV and platelet antigens, decreased platelet survival,
decreased production, and infection of megakaryocytes [113]. With concurrent thrombocytopenia,
the relative monocytopenia observed in poor recovery may be an indicator of suppressed
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hematopoiesis. However, there was no association between neutrophil count and CD4 recovery.
Given that both T lymphocytes and monocytes are natural hosts for HIV infection and replication,
it cannot be excluded that poor CD4 recovery may reflect persistent HIV infection and subclinical
replication in both T lymphocytes and monocytes that suppresses their cell counts. A higher
hemoglobin was observed in suboptimal versus complete recovery post-ART, contrary to other
reports [114].
Poor CD4 recovery trended towards association with neuroinflammation at baseline, as
measured by CSF neopterin. However, when controlling for confounders, there was no
independent association between CSF neopterin and CD4 recovery. To our knowledge, this is the
first study assessing the association between neuroinflammation and impaired CD4 recovery,
though other CNS biomarkers have been associated with CD4 recovery [115]. Elevated CSF
neopterin has been associated with CSF HIV-RNA and neurological complications of HIV
infection [116]. Elevated plasma neopterin has been associated with poor CD4 recovery in treated
HIV infection [117]. Suboptimal CD4 recovery may reflect not just a systemic inflammatory state
but also a localized neuroinflammatory state, which may have implications for neurological
outcomes in poor responders. Further work is needed to investigate associations between CD4
recovery and localized inflammation.
We did not find an association between CD4 recovery and coinfection with syphilis,
hepatitis B virus, or hepatitis C virus. Our study may not be sufficiently powered to detect an
association between CD4 recovery and HCV coinfection, given the low number of positive antiHCV samples. Some studies have not shown an association between HBV coinfection and CD4
recovery [118], while others have [119]. Likewise, HCV coinfection has been associated with poor
CD4 recovery on ART in some studies [120] but not others [121].
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A subset of participants was assessed for CD4+ and CD8+ T cell activation by flow
cytometry of CD38+ T cell subsets. However, sample sizes were too low to assess for an
association between immunological response and CD38+ expression. CD38+ expression in CD8+
T cells has been associated with a faster rate of CD4+ T cell decline in untreated individuals with
HIV [122]. Additionally, higher expression of immune checkpoint receptor and exhaustion marker
PD-1 on both CD4+ and CD8+ T cells has been associated with lower CD4 count at baseline and
after treatment [24, 123]. This was not assessed in this study of acute HIV infection and is a target
for future investigation. Further work is also needed to assess whether expression of IL-7 receptor,
regulatory T cell phenotype, and inflammasome upregulation is associated with immunological
response in acute HIV infection, as described in treated chronic HIV infection [124-126].
Our study has several limitations. On-ART factors were measured at the week of the latest
available study visit, which was lower in the combined suboptimal and intermediate recovery
group compared to complete recovery. Thus, the overall longer treatment duration in the complete
recovery group possibly confounds the finding of improved CD4+ T cell gains. However, our
slope analysis examines rate of recovery over a fixed time interval, showing that the complete
recovery group exhibits both higher and faster CD4 recovery. Furthermore, we identified pre- and
on-ART factors independently associated with poor CD4 recovery < 500 cells/mm3 when adjusting
for duration of ART, as well as baseline CD4 count and HIV-RNA. Our study did not have
sufficient numbers of lumbar punctures after 48 weeks of ART and thus cannot assess the degree
of neuroinflammation after ART in poor responders. The participants in this study are young and
may have a lower baseline inflammatory state due to young age. Finally, the HIV-uninfected Thai
population have a lower CD4+ T cell count reference range compared to predominantly white or
European reference populations [127].
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CSF Escape in Acute HIV Infection
We found that after immediate ART initiation in acute HIV infection, there is a very low
incidence of CSF escape of 1% after 24 weeks and 0% after 96 weeks. Moreover, the singular case
of CSF escape identified in our study population was at a low CSF viral load of 316 copies/mL
and was not associated with any neurological findings or dysfunction. Prior studies have identified
an incidence rate of up to 10% for CSF escape in the setting of treated chronic HIV infection [81],
though a follow-up study by the same authors suggested that many of these cases of detectable and
quantifiable CSF HIV RNA are likely better described as CSF viral blips since the CSF viral loads
mostly are not repeatedly elevated on longitudinal measurements [91]. This episodic CSF viral
blip may be mechanistically due to cell trafficking into the CNS, resulting in either HIV release or
transient viral replication [41]. Thus, it remains fairly likely that this case of asymptomatic
quantifiable CSF HIV RNA paired with undetectable plasma HIV RNA can be considered a CSF
viral blip. This may be further corroborated by the lack of CSF pleocytosis. Of note, even with
CSF viral blips, there may be an association between low-level CSF HIV RNA and increased
neuroinflammation as measured by elevated CSF neopterin levels [91].
An additional consideration is the possibility that this singular case represents secondary
CSF escape, given the nonreactive VDRL at baseline and the reactive VDRL at week 96. Although
we cannot know when this participant was infected with syphilis, an infection at week 24 cannot
be excluded as a possible contributor for CSF escape secondary to neurosyphilis. In secondary
CSF escape, elevated CSF HIV RNA is thought to be due to a superimposed infection or
inflammatory process causing increased immune cell trafficking into the CNS, which results in
localized viral replication detectable in CSF [83]. Again, the lack of CSF pleocytosis speaks
against this possibility.
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Prior characterizations of this unique AHI cohort have described baseline characteristics
of early CNS infection. At baseline, most of our participants had detectable HIV RNA in the CSF,
and none had CSF HIV RNA greater than that in plasma [55]. AHI individuals with a higher CSF
HIV RNA relative to plasma HIV RNA have a greater degree of systemic inflammation as
measured by CD4/CD8 ratio and a greater degree of neuroinflammation as measured by CSF
neopterin, soluble CD163, IL-6, and sCD14 [128]. From our results, CSF HIV RNA is almost
always suppressed to undetectable levels when initiating ART in AHI with only one case of CSF
escape. Further work is needed to characterize whether CSF escape in AHI is associated with
neurological or systemic inflammation. Additionally, since the incidence of CSF escape has been
associated with longer time on ART in chronic infection [81], long-term follow-up of this cohort
is necessary to verify that CSF escape remains rare in treated AHI. The rarity of CSF escape in
treated AHI may point to a benefit in very early treatment in terms of reducing CNS persistence
and viral reservoirs, though further investigation is needed [40].
This study has several limitations. This singular case of CSF escape was identified in a
participant who to date has undergone only one study lumbar puncture, with no CSF samples prior
to ART initiation nor at any other study visit. Thus, it is impossible to determine whether the
quantifiable CSF HIV RNA at week 24 has been sustained and to distinguish between persistent
CSF escape and a CSF viral blip. The level of 316 copies/mL is too low to perform resistance
testing using available assays, but further testing could be useful in determining whether selection
for drug resistance is driving this case of CSF escape and determining any degree of
compartmentalization between blood and the CNS. Further testing could also assess the virological
phenotype of this CSF escape population, namely its propensity to infect macrophages (M-tropic)
versus CD4+ T cells (T-tropic), which may provide additional clues about whether the population
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is produced by CNS reservoirs versus transient immune cell trafficking [41]. We did not measure
any other markers in CSF, such as neopterin and sCD14, in this participant. Additionally, with
only one case of CSF escape, we cannot draw any statistically significant associations with markers
of neuroinflammation or systemic inflammation. In the cohort at large, markers of immune
activation in CSF but not plasma normalize after 96 weeks of ART [58]. Finally, due to sample
dilution for volume requirements for CSF, the lower limit of quantification of HIV RNA differs
between CSF and plasma, and thus our study cannot capture very low-level CSF HIV RNA < 80
copies/mL that may represent cases of CSF escape or CSF viral blips. Recent work has
demonstrated that even low-level CSF HIV RNA < 20 copies/mL associates with decreased bloodbrain barrier integrity and executive function [90].

Conclusions
In conclusion, suboptimal CD4 recovery following initiation of ART during AHI is low (<
5%) compared to chronic HIV infection and is characterized by a low CD4 count at baseline and
persistent low CD8 count during treatment. Poor recovery is also associated with systemic
inflammation during treatment. CSF escape is rare (1%) following initiation of ART during AHI.
Future work should be directed at determining whether ART should be initiated as early as possible
in AHI versus strategic timing of ART within AHI to coincide with spontaneous CD4 recovery in
order to optimize long-term CD4 recovery [71]. Future work should also corroborate the low
incidence of CSF escape over longer follow-up > 96 weeks and investigate the virological drivers
behind CSF escape in treated AHI.
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List of Abbreviations
AHI, acute HIV infection; anti-HBs, hepatitis B surface antibody; ART, antiretroviral therapy;
CBC, complete blood count; CD4, CD4+ T cell; CD8, CD8+ T cell; CI, confidence interval; CNS,
central nervous system; CR, complete recovery; CSF, cerebrospinal fluid; ELISA, enzyme-linked
immunosorbent assay; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; I-FABP, intestinal fatty acid binding protein; IL-6, interleukin-6; IQR,
interquartile range; IR, intermediate recovery; MSM, men who have sex with men; MSW, men
who have sex with women; NPZ-4, neuropsychological test z-score in four domains (Color Trails
1, Color Trails 2, Trail Making A, Grooved Pegboard); OR, odds ratio; PHQ, Patient Health
Questionnaire; TNF-alpha, tumor necrosis factor alpha, sCD14, soluble CD14; SR, suboptimal
recovery; VDRL, Venereal Disease Research Laboratory test; WBC, white blood cell; WSM,
women who have sex with men.
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